Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Recombinant erythropoietin in clinical practice.

Literature DB >> 12897214

Recombinant erythropoietin in clinical practice.

T Ng¹, G Marx, T Littlewood, I Macdougall.

Abstract

The introduction of recombinant human erythropoietin (RHuEPO) has revolutionised the treatment of patients with anaemia of chronic renal disease. Clinical studies have demonstrated that RHuEPO is also useful in various non-uraemic conditions including haematological and oncological disorders, prematurity, HIV infection, and perioperative therapies. Besides highlighting both the historical and functional aspects of RHuEPO, this review discusses the applications of RHuEPO in clinical practice and the potential problems of RHuEPO treatment.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2003 PMID： 12897214 PMCID： PMC1742767 DOI： 10.1136/pmj.79.933.367

Source DB: PubMed Journal: Postgrad Med J ISSN： 0032-5473 Impact factor: 2.401

89 in total

1. Subcutaneous low-dose epoetin beta for the avoidance of transfusion in patients scheduled for elective surgery not eligible for autologous blood donation.

Authors: C Wurnig; K Schatz; H Noske; Y Hemon; G Dahlberg; G Josefsson; J Milbrink; C Hamard
Journal: Eur Surg Res Date: 2001 Sep-Dec Impact factor: 1.745

2. Primary and revision total hip replacement in patients who are Jehovah's Witnesses.

Authors: C L Nelson; J G Stewart
Journal: Clin Orthop Relat Res Date: 1999-12 Impact factor: 4.176

Review 3. Erythropoietin: the promise and the facts.

Authors: J W Eschbach
Journal: Kidney Int Suppl Date: 1994-01 Impact factor: 10.545

Review 4. The impact of hemoglobin levels on treatment outcomes in patients with cancer.

Authors: T J Littlewood
Journal: Semin Oncol Date: 2001-04 Impact factor: 4.929

5. Anemia and survival in HIV infection.

Authors: R D Moore; J C Keruly; R E Chaisson
Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1998-09-01

Review 6. Consensus statement: anemia in HIV infection--current trends, treatment options, and practice strategies. Anemia in HIV Working Group.

Authors: P Volberding
Journal: Clin Ther Date: 2000-09 Impact factor: 3.393

Review 7. Anaemia of prematurity. Epidemiology, management and costs.

Authors: M P Meyer
Journal: Pharmacoeconomics Date: 1997-10 Impact factor: 4.981

Review 8. CMV and blood transfusions.

Authors: John D Roback
Journal: Rev Med Virol Date: 2002 Jul-Aug Impact factor: 6.989

9. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies.

Authors: E Hellström-Lindberg
Journal: Br J Haematol Date: 1995-01 Impact factor: 6.998

10. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials.

Authors: D H Henry; G N Beall; C A Benson; J Carey; L A Cone; L J Eron; M Fiala; M A Fischl; S J Gabin; M S Gottlieb
Journal: Ann Intern Med Date: 1992-11-01 Impact factor: 25.391

31 in total

1. Effects of Human Erythropoietin on Functional Outcome of Patients with Traumatic Cervical Cord Injury; A Pilot Randomized Clinical Trial.

Authors: Ehsan Ali Alibai; Fahim Baghban; Majid Reza Farrokhi; Navideh Mohebali; Mohammad Hossein Ashraf
Journal: Bull Emerg Trauma Date: 2015-07

Review 2. Harms of off-label erythropoiesis-stimulating agents for critically ill people.

Authors: Bita Mesgarpour; Benedikt H Heidinger; Dominik Roth; Susanne Schmitz; Cathal D Walsh; Harald Herkner
Journal: Cochrane Database Syst Rev Date: 2017-08-25

Review 3. The Promises and Challenges of Erythropoietin for Treatment of Alzheimer's Disease.

Authors: Jiahong Sun; Jan Michelle Martin; Victoria Vanderpoel; Rachita K Sumbria
Journal: Neuromolecular Med Date: 2019-01-17 Impact factor: 3.843

4. The Endoplasmic Reticulum Cargo Receptor SURF4 Facilitates Efficient Erythropoietin Secretion.

Authors: Zesen Lin; Richard King; Vi Tang; Greggory Myers; Ginette Balbin-Cuesta; Ann Friedman; Beth McGee; Karl Desch; Ayse Bilge Ozel; David Siemieniak; Pavan Reddy; Brian Emmer; Rami Khoriaty
Journal: Mol Cell Biol Date: 2020-11-06 Impact factor: 4.272

5. Pharmacokinetic and Pharmacodynamic Comparison of Two Recombinant Human Erythropoietin Formulations, PDA10 and Eprex, in Healthy Korean Male Volunteers: A Randomized, Double-Blinded, Single-Dose, Two-Period Crossover Study.

Authors: MinKyung Oh; Jaeseung Yoon; Doo-Yeoun Cho
Journal: Clin Drug Investig Date: 2015-10 Impact factor: 2.859

Review 6. Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach.

Authors: Zahra Moradi; Amirhosein Maali; Javad Sadeghi Shad; Alireza Farasat; Reza Kouchaki; Mona Moghadami; Mohamad Hosein Ahmadi; Mehdi Azad
Journal: Indian J Hematol Blood Transfus Date: 2019-09-16 Impact factor: 0.900

Review 7. Erythropoietin pharmacology.

Authors: J M Jurado García; E Torres Sánchez; D Olmos Hidalgo; E Alba Conejo
Journal: Clin Transl Oncol Date: 2007-11 Impact factor: 3.405